93 related articles for article (PubMed ID: 22784120)
1. Antibodies to potassium channels in multiple sclerosis.
Cross AH; Waubant E
N Engl J Med; 2012 Jul; 367(2):172-4. PubMed ID: 22784120
[No Abstract] [Full Text] [Related]
2. Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: different methodologies--conflicting results?
Hemmer B
Mult Scler; 2015 Apr; 21(5):537-9. PubMed ID: 25583849
[No Abstract] [Full Text] [Related]
3. Multiple Sclerosis and Antibodies against KIR4.1.
Pröbstel AK; Kuhle J; Lecourt AC; Vock I; Sanderson NS; Kappos L; Derfuss T
N Engl J Med; 2016 Apr; 374(15):1496-8. PubMed ID: 27074084
[No Abstract] [Full Text] [Related]
4. Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis.
Chastre A; Hafler DA; O'Connor KC
N Engl J Med; 2016 Apr; 374(15):1495-6. PubMed ID: 27074083
[No Abstract] [Full Text] [Related]
5. Potassium channel KIR4.1 as an immune target in multiple sclerosis.
Srivastava R; Aslam M; Kalluri SR; Schirmer L; Buck D; Tackenberg B; Rothhammer V; Chan A; Gold R; Berthele A; Bennett JL; Korn T; Hemmer B
N Engl J Med; 2012 Jul; 367(2):115-23. PubMed ID: 22784115
[TBL] [Abstract][Full Text] [Related]
6. Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis.
Nerrant E; Salsac C; Charif M; Ayrignac X; Carra-Dalliere C; Castelnovo G; Goulabchand R; Tisseyre J; Raoul C; Eliaou JF; Labauge P; Vincent T
Mult Scler; 2014 Nov; 20(13):1699-703. PubMed ID: 24756568
[TBL] [Abstract][Full Text] [Related]
7. Anti-Kir4.1 Antibodies in Multiple Sclerosis: Specificity and Pathogenicity.
Imamura M; Higuchi O; Maeda Y; Mukaino A; Ueda M; Matsuo H; Nakane S
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348803
[TBL] [Abstract][Full Text] [Related]
8. Disease mechanisms in MS: the potassium channel KIR4.1--a potential autoantigen in MS.
Racke MK
Nat Rev Neurol; 2012 Nov; 8(11):595-6. PubMed ID: 22986435
[TBL] [Abstract][Full Text] [Related]
9. Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease.
Kraus V; Srivastava R; Kalluri SR; Seidel U; Schuelke M; Schimmel M; Rostasy K; Leiz S; Hosie S; Grummel V; Hemmer B
Neurology; 2014 Feb; 82(6):470-3. PubMed ID: 24415573
[TBL] [Abstract][Full Text] [Related]
10. Low reliability of anti-KIR4.1
Marino M; Frisullo G; Di Sante G; Samengo DM; Provenzano C; Mirabella M; Pani G; Ria F; Bartoccioni E
Mult Scler; 2018 Jun; 24(7):910-918. PubMed ID: 28548026
[TBL] [Abstract][Full Text] [Related]
11. Antimyelin antibodies in multiple sclerosis.
Maguire GA
N Engl J Med; 2003 Dec; 349(23):2269-71; author reply 2269-71. PubMed ID: 14657439
[No Abstract] [Full Text] [Related]
12. Increased anti-KIR4.1 antibodies in multiple sclerosis: could it be a marker of disease relapse?
Brill L; Goldberg L; Karni A; Petrou P; Abramsky O; Ovadia H; Ben-Hur T; Karussis D; Vaknin-Dembinsky A
Mult Scler; 2015 Apr; 21(5):572-9. PubMed ID: 25392324
[TBL] [Abstract][Full Text] [Related]
13. Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis.
Malyavantham K; Weinstock-Guttman B; Suresh L; Zivadinov R; Shanahan T; Badgett D; Ramanathan M
PLoS One; 2015; 10(6):e0129503. PubMed ID: 26065913
[TBL] [Abstract][Full Text] [Related]
14. Detection of potassium channel KIR4.1 antibodies in Multiple Sclerosis patients.
Marnetto F; Valentino P; Caldano M; Bertolotto A
J Immunol Methods; 2017 Jun; 445():53-58. PubMed ID: 28300540
[TBL] [Abstract][Full Text] [Related]
15. Antimyelin antibodies in multiple sclerosis.
Mantegazza R
N Engl J Med; 2003 Dec; 349(23):2269-71; author reply 2269-71. PubMed ID: 14663868
[No Abstract] [Full Text] [Related]
16. Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review.
Navas-Madroñal M; Valero-Mut A; Martínez-Zapata MJ; Simón-Talero MJ; Figueroa S; Vidal-Fernández N; López-Góngora M; Escartín A; Querol L
PLoS One; 2017; 12(4):e0175538. PubMed ID: 28414733
[TBL] [Abstract][Full Text] [Related]
17. Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults.
Wang H; Munger KL; Reindl M; O'Reilly EJ; Levin LI; Berger T; Ascherio A
Neurology; 2008 Oct; 71(15):1142-6. PubMed ID: 18753473
[TBL] [Abstract][Full Text] [Related]
18. Gluten sensitivity in multiple sclerosis: experimental myth or clinical truth?
Shor DB; Barzilai O; Ram M; Izhaky D; Porat-Katz BS; Chapman J; Blank M; Anaya JM; Shoenfeld Y
Ann N Y Acad Sci; 2009 Sep; 1173():343-9. PubMed ID: 19758171
[TBL] [Abstract][Full Text] [Related]
19. [Anti-optic neuromyelitis IgG antibodies and neuropsychiatric manifestations in systemic lupus erythematosus].
Gómiz Rodrígez G; López Robles C; Callejas Rubio JL; Ortego Centeno N
Med Clin (Barc); 2010 May; 134(13):614. PubMed ID: 19819483
[No Abstract] [Full Text] [Related]
20. NMO-IgG in the diagnosis of neuromyelitis optica.
Jarius S; Franciotta D; Bergamaschi R; Wright H; Littleton E; Palace J; Hohlfeld R; Vincent A
Neurology; 2007 Mar; 68(13):1076-7. PubMed ID: 17287449
[No Abstract] [Full Text] [Related]
[Next] [New Search]
